YOUR HELP IS URGENTLY NEEDED! (Canadians and Non-Canadians Welcome to Participate). Input Needed Before August 15, 2017. Did you or someone you love fail treatment with one of the new interferon-free “DAAs”? Worried about “treatment-resistant” hepatitis C viruses developing? Here’s a new treatment that could help solve these problems. If you are a patient (current or former) or caregiver with an opinion on whether a treatment like this should (or shouldn’
URGENT! Patient and Caregiver Input Request: We Need to Hear your Voice! Patient and Caregiver input is requested by CADTH on AbbVie’s BRAND NEW (not yet for sale in Canada!) combo of glecaprevir and pibrentasvir (G/P) for Genotypes 1-6. AbbVie’s G/P combo is pan-genotypic (works for all genotypes). Check out the background information in links below to see the results that have been achieved in clinical trials to date. You will see that the cure rates
Epclusa™, a Direct-Acting-Antiviral combo for ALL GENOTYPES of Chronic Hepatitis C, received approval from CADTH on October 28, 2016. This combo of (generics) sofosbuvir and velpatasvir, from Gilead Sciences, was recommended by CADTH's Canadian Drug Expert Committtee (CDEC) for reimbursement by provincial and territorial PharmaCares... "if the following CRITERION and CONDITION are met: (1) CONDITION: "Reduce the price." CDEC noted that the cost of t
A Hep C treatment option for ALL genotypes? What do YOU think about this? Hello! Once again, HepCBC is calling for your input. BC PharmaCare is reviewing whether to add another Direct Acting-Antiviral (DAA) for hepatitis C to its formulary (list of drugs it will cover) Patient and Caregiver input is requested by BC PharmaCare on Gilead’s combo of sofosbuvir and velpatasvir for Genotypes 1-6 (brand name: Epclusa®). Gilead’s combo is the first pan-gen
We want to hear your voice! Patient input is requested by CADTH on Gilead’s combo of sofosbuvir and velpatasvir for genotypes 1, 3 and 4. ANYONE AFFECTED BY HEPATITIS C CAN SUBMIT; it doesn't matter which genotype you are, or if you haven't had any experience with this new treatment. Gilead’s combo is pan-genotypic (works for all genotypes). Check out the background information below to see the results from clinical trials to date. You will see that the
Zepatier™ (grazoprevir / elbasvir [± ribavirin]) Merck’s combo was approved by the FDA in January: http://www.mercknewsroom.com/news-release/prescription-medicine-news/merck-receives-fda-approval-zepatier-elbasvir-and-grazoprevi and was also approved in Canada for genotypes 1, 3 and 4 in early February: http://hepcbc.ca/2016/02/merck-receives-approval-of-zepatier-elbasvirgrazoprevir-in-canada-for-the-treatment-of-chronic-hepatitis-c-for-patients-...
PATIENT GROUP SUBMISSIONS to BC PharmaCare and CADTH Whenever we are asked to contribute a patient group submission about a hepatitis-C or hepatitis-B related product, we do so. We contribute as a patient group to reviews by both BC PharmaCare (to determine whether BC PharmaCare patients will be reimbursed for the drugs) and CADTH (federal level – to determine whether the drugs will be available in Canada). Below are the submissions we have made, from